US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
US6887471B1
(en)
*
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
US20050002902A1
(en)
*
|
1995-12-28 |
2005-01-06 |
Liming Yu |
Hybrid with interferon-alpha and an immunoglobulin Fc for treatment of tumors and viral infections
|
US6750334B1
(en)
*
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
EP0892643B2
(de)
*
|
1996-03-20 |
2009-09-02 |
Bristol-Myers Squibb Company |
Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
WO1999015552A1
(fr)
*
|
1997-09-19 |
1999-04-01 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Composes oligopeptidiques
|
EP1037927B1
(de)
|
1997-12-08 |
2004-05-19 |
Lexigen Pharmaceuticals Corp. |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ES2267263T3
(es)
*
|
1998-04-15 |
2007-03-01 |
Emd Lexigen Research Center Corp. |
Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
|
IL126681A0
(en)
*
|
1998-10-21 |
1999-08-17 |
Opperbas Holding Bv |
Treatment of trauma-related conditions
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
BR0010725A
(pt)
*
|
1999-05-19 |
2002-02-19 |
Lexigen Pharm Corp |
Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
DK1200479T3
(da)
*
|
1999-08-09 |
2006-05-15 |
Emd Lexigen Res Ct Corp |
Multiple cytokin-antistof-komplekser
|
MXPA02001877A
(es)
|
1999-08-23 |
2002-08-20 |
Dana Farber Cancer Inst Inc |
Pd-1, un receptor para b7-4, y usos del mismo.
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
CA2399832C
(en)
|
2000-02-11 |
2011-09-20 |
Stephen D. Gillies |
Enhancing the circulating half-life of antibody-based fusion proteins
|
IL151348A0
(en)
|
2000-04-13 |
2003-04-10 |
Univ Rockefeller |
Enhancement of antibody-mediated immune responses
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
US7094874B2
(en)
*
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
CA2411962A1
(en)
*
|
2000-06-09 |
2001-12-20 |
Bristol-Myers Squibb Company |
Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
|
AU2001273096B8
(en)
|
2000-06-28 |
2005-10-13 |
Dana-Farber Cancer Institute, Inc. |
PD-L2 molecules: novel PD-1 ligands and uses therefor
|
DK1294401T3
(da)
*
|
2000-06-29 |
2007-10-08 |
Merck Patent Gmbh |
Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
|
TR201807700T4
(tr)
*
|
2000-07-03 |
2018-06-21 |
Squibb Bristol Myers Co |
Çözünür CTLA4 mutant moleküllerinin kullanımları.
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
EP1179587A1
(de)
*
|
2000-08-09 |
2002-02-13 |
Genethor GmbH |
Verfahren zur Reduzierung von spezifischen Immunreaktionen
|
ES2311560T3
(es)
*
|
2000-12-07 |
2009-02-16 |
Eli Lilly And Company |
Proteinas de fusion glp-1.
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
HUP0303930A3
(en)
*
|
2001-01-26 |
2012-09-28 |
Univ Emory |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
AU2002248571B2
(en)
*
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
MXPA03008959A
(es)
|
2001-04-02 |
2004-10-15 |
Wyeth Corp |
Pd-1, un receptor para b7-4 y sus usos.
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
BR0209177A
(pt)
*
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
DE60225914T2
(de)
*
|
2001-05-23 |
2009-07-23 |
Bristol-Myers Squibb Co. |
Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
|
KR100453877B1
(ko)
*
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
US7737260B2
(en)
|
2003-11-13 |
2010-06-15 |
Hanmi Pharm. Co., Ltd |
Protein complex using an immunoglobulin fragment and method for the preparation thereof
|
EP2354791A1
(de)
*
|
2001-12-04 |
2011-08-10 |
Merck Patent GmbH |
Immunocytokine mit modulierter Selektivität
|
US20030144193A1
(en)
*
|
2001-12-20 |
2003-07-31 |
Rottman James B. |
TANGO 197 and TANGO 216 compositions and methods
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
AU2003222141A1
(en)
*
|
2002-03-29 |
2003-10-13 |
Repligen Corporation |
Ctla4 compositions in the treatment of autism
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
EP1633786A4
(de)
*
|
2002-10-09 |
2007-07-25 |
Rinat Neuroscience Corp |
Verfahren zur behandlung der alzheimer-krankheit mit antikörpern gegen amyloid-beta-peptid und zusammensetzungen daraus
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
BRPI0317376B8
(pt)
|
2002-12-17 |
2021-05-25 |
Merck Patent Gmbh |
proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
|
CN100402660C
(zh)
*
|
2002-12-23 |
2008-07-16 |
布里斯托尔-迈尔斯斯奎布公司 |
用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
|
TWI312368B
(en)
*
|
2002-12-23 |
2009-07-21 |
Bristol Myers Squibb Compan |
Mammalian cell culture processes for protein production
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
JP2007527696A
(ja)
*
|
2003-04-03 |
2007-10-04 |
ラボラトワール フランセ デュ フラクションヌメント エ デ バイオテクノロジーズ |
細胞機能を調節する能力が増強された治療産物
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
AU2004251145C1
(en)
|
2003-06-12 |
2011-04-14 |
Eli Lilly And Company |
GLP-1 analog fusion proteins
|
SI1641483T1
(sl)
*
|
2003-06-12 |
2008-08-31 |
Lilly Co Eli |
Fuzijski proteini
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
WO2005016266A2
(en)
*
|
2003-08-04 |
2005-02-24 |
Bristol-Myers Squibb Company |
Methods for treating cardiovascular disease using a soluble ctla4 molecule
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
JP2007531707A
(ja)
|
2003-10-15 |
2007-11-08 |
ピーディーエル バイオファーマ, インコーポレイテッド |
IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
|
AU2004287431B2
(en)
*
|
2003-10-27 |
2010-03-11 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
US20050238651A1
(en)
*
|
2003-11-25 |
2005-10-27 |
Gurtner Gregory J |
Treatment of inflammatory bowel disease
|
WO2005051321A2
(en)
*
|
2003-11-25 |
2005-06-09 |
Washington University |
Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase
|
RU2369616C2
(ru)
|
2003-12-30 |
2009-10-10 |
Мерк Патент Гмбх |
Слитые белки il-7
|
AU2004309063B2
(en)
*
|
2003-12-31 |
2010-10-28 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
WO2005066348A2
(en)
*
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
EP1737890A2
(de)
*
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulinvarianten ausserhalb der fc-region
|
KR101297146B1
(ko)
|
2004-05-10 |
2013-08-21 |
마크로제닉스, 인크. |
인간화 FcγRIIB 특이적 항체 및 그의 사용 방법
|
KR100542605B1
(ko)
*
|
2004-05-28 |
2006-01-11 |
보령제약 주식회사 |
에이치씨티엘에이4-아이지 융합단백질 유전자를 포함하는재조합 벡터 및 이를 이용한 에이치씨티엘에이4-아이지융합 단백질의 생산방법
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
AU2005203329B2
(en)
*
|
2004-07-28 |
2011-10-27 |
Global Water Collectors Pty Ltd |
Catchment surface for collection of water precipitate
|
KR100864549B1
(ko)
|
2004-08-04 |
2008-10-20 |
어플라이드 몰리큘라 에볼류션, 인코포레이티드 |
변이체 fc 영역
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
KR101027427B1
(ko)
|
2004-11-12 |
2011-04-11 |
젠코어 인코포레이티드 |
FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
CA2591297C
(en)
*
|
2004-12-09 |
2015-01-13 |
Stephen D. Gillies |
Il-7 variants with reduced immunogenicity
|
WO2006093794A1
(en)
*
|
2005-02-28 |
2006-09-08 |
Centocor, Inc. |
Heterodimeric protein binding compositions
|
US20100104564A1
(en)
*
|
2005-03-29 |
2010-04-29 |
Genevieve Hansen |
Altered Antibody Fc Regions and Uses Thereof
|
CA2603970A1
(en)
*
|
2005-04-06 |
2006-10-12 |
Bristol-Myers Squibb Company |
Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
|
EP3479844B1
(de)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Kovalente diabodies und verwendungen davon
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
UA97469C2
(uk)
|
2005-07-25 |
2012-02-27 |
Емерджент Продакт Дівелопмент Сіетл, Елелсі |
Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
|
US8217147B2
(en)
|
2005-08-10 |
2012-07-10 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
US9868961B2
(en)
*
|
2006-03-30 |
2018-01-16 |
The Regents Of The University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
WO2008105886A2
(en)
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
EP2032159B1
(de)
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
PT2059536E
(pt)
|
2006-08-14 |
2014-04-14 |
Xencor Inc |
Anticorpos otimizados que visam cd19
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
EP2560001B1
(de)
*
|
2006-09-21 |
2016-04-13 |
University of Rochester |
Zusammensetzungen und Verfahren für eine Proteinverlagerungstherapie für myotone Dystrophie
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
ES2565834T3
(es)
|
2007-06-01 |
2016-04-07 |
University Of Maryland, Baltimore |
Agentes de unión a receptor de Fc de región constante de inmunoglobulina
|
BRPI0814465B1
(pt)
|
2007-07-26 |
2021-11-23 |
Novagen Holding Corporation |
Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
|
EP2612868B1
(de)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunsuppressive Polypeptide und Nucleinsäuren
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
SI2235059T1
(sl)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variante s spremenjeno vezjo na fcrn
|
JP5541845B2
(ja)
*
|
2008-03-28 |
2014-07-09 |
Jcrファーマ株式会社 |
アトピー性皮膚炎治療剤
|
CN106349390B
(zh)
|
2008-04-02 |
2019-12-10 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
PL2247304T3
(pl)
|
2008-04-02 |
2017-01-31 |
Macrogenics, Inc. |
Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
|
NZ603059A
(en)
*
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US7915222B2
(en)
*
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
MX2011000861A
(es)
|
2008-07-23 |
2011-06-21 |
Hanmi Holdings Co Ltd |
Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales.
|
RS54233B1
(en)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION
|
US20110159023A1
(en)
*
|
2008-08-25 |
2011-06-30 |
Solomon Langermann |
Pd-1 antagonists and methods for treating infectious disease
|
MX338825B
(es)
|
2008-10-02 |
2016-05-03 |
Emergent Product Dev Seattle |
Proteinas de enlace a objetivos multiples de antagonistas de cd86.
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
AU2010233995A1
(en)
|
2009-04-07 |
2011-09-08 |
Roche Glycart Ag |
Bispecific anti-ErbB-2/anti-c-Met antibodies
|
EP2417159A1
(de)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Bispezifische anti-erbb-3/anti-c-met-antikörper
|
MX2011011044A
(es)
*
|
2009-04-22 |
2011-11-04 |
Merck Patent Gmbh |
Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
|
SG176219A1
(en)
|
2009-05-27 |
2011-12-29 |
Hoffmann La Roche |
Tri- or tetraspecific antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
WO2011018225A1
(en)
|
2009-08-14 |
2011-02-17 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
NZ598962A
(en)
|
2009-09-16 |
2014-12-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
RU2583298C2
(ru)
|
2009-10-07 |
2016-05-10 |
Макродженикс, Инк. |
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
MY161909A
(en)
|
2009-12-22 |
2017-05-15 |
Roche Glycart Ag |
Anti-her3 antibodies and uses thereof
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
NZ602161A
(en)
|
2010-03-04 |
2014-12-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
WO2011109280A1
(en)
|
2010-03-05 |
2011-09-09 |
Lerner Research Institute |
Methods and compositions to treat immune-mediated disorders
|
CN106432474A
(zh)
|
2010-03-12 |
2017-02-22 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CA2795544A1
(en)
|
2010-04-27 |
2011-11-03 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
MX368531B
(es)
|
2010-07-28 |
2019-10-07 |
Gliknik Inc |
Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
|
JP5964300B2
(ja)
|
2010-08-02 |
2016-08-03 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディおよびその使用
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
CN103261229A
(zh)
|
2010-12-16 |
2013-08-21 |
罗切格利卡特公司 |
无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
MX341921B
(es)
|
2011-02-28 |
2016-09-07 |
Hoffmann La Roche |
Proteinas de union a antigeno.
|
MX354359B
(es)
|
2011-03-29 |
2018-02-28 |
Roche Glycart Ag |
Variantes de fragmento cristalizable (fc) de los anticuerpos.
|
US20140147418A1
(en)
*
|
2011-04-15 |
2014-05-29 |
The Us Of America, As Represented By The Secretary Department Of Health And Human Services |
Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
|
EP2709653B1
(de)
|
2011-04-20 |
2017-11-22 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Aav-vermittelter exendin-4-gentransfer in die speicheldrüsen zum schutz vor diabetes oder adipositas
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
KR102046666B1
(ko)
|
2011-05-25 |
2019-11-19 |
이나뜨 파르마 |
염증성 장애의 치료를 위한 항-kir 항체
|
CA2845147A1
(en)
|
2011-09-23 |
2013-03-28 |
Roche Glycart Ag |
Bispecific anti-egfr/anti igf-1r antibodies
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
WO2013112986A1
(en)
*
|
2012-01-27 |
2013-08-01 |
Gliknik Inc. |
Fusion proteins comprising igg2 hinge domains
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
US9758566B2
(en)
*
|
2012-03-29 |
2017-09-12 |
The General Hospital Corporation |
Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
|
ES2777778T3
(es)
|
2012-05-11 |
2020-08-06 |
Medimmune Ltd |
Variantes de CTLA-4
|
KR20150013188A
(ko)
|
2012-05-24 |
2015-02-04 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체
|
US8735359B2
(en)
*
|
2012-05-24 |
2014-05-27 |
Orban Biotech Llc |
Combinations of modalities for the treatment of diabetes
|
EP2864352B1
(de)
|
2012-06-22 |
2018-08-08 |
The Trustees Of Dartmouth College |
Neuartige vista-ig-konstrukte und verwendung von vista-ig zur behandlung von autoimmun-, allergischen und entzündungserkrankungen
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
EP2867253B1
(de)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Verfahren zur auswahl und herstellung massgeschneiderter, hochselektiver und multispezifischer targeting-einheiten mit mindestens zwei verschiedenen bindungseinheiten sowie verwendungen davon
|
CA2877986A1
(en)
|
2012-06-27 |
2014-01-03 |
Orban Biotech Llc |
Ctla4 fusion proteins for the treatment of diabetes
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
HUE056217T2
(hu)
|
2012-07-13 |
2022-02-28 |
Roche Glycart Ag |
Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
|
WO2014022759A1
(en)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
EP2885320A4
(de)
|
2012-08-20 |
2016-04-06 |
Gliknik Inc |
Moleküle mit antigenbindender und polyvalenter fc-gamma-rezeptorbindender aktivität
|
ES2729561T3
(es)
|
2012-08-31 |
2019-11-04 |
Us Health |
Transferencia del gen acuaporina mediada por un virus adenoasociado (aav) para el tratamiento del síndrome de Sjögren
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
MX2015012709A
(es)
|
2013-03-14 |
2016-05-31 |
Macrogenics Inc |
Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
MX369173B
(es)
|
2013-12-24 |
2019-10-30 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
GB2523399B
(en)
|
2014-02-25 |
2019-03-13 |
Orban Tihamer |
A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
JP6691872B2
(ja)
|
2014-05-30 |
2020-05-13 |
ヘンリクス バイオテック カンパニー リミテッド |
抗上皮増殖因子受容体(egfr)抗体
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
EP3201227A4
(de)
|
2014-09-29 |
2018-04-18 |
Duke University |
Bispezifische moleküle mit einem hiv-1-hüll-targeting-arm
|
PL3221359T3
(pl)
|
2014-11-17 |
2020-11-16 |
Regeneron Pharmaceuticals, Inc. |
Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
EP3229837A4
(de)
|
2014-12-08 |
2018-05-30 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur hochregulierung von immunantworten unter verwendung von kombinationen aus anti-rgmb- und anti-pd1-wirkstoffen
|
US9512229B2
(en)
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
AU2016242866B2
(en)
|
2015-03-30 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to FC gamma receptors
|
DK3283508T3
(en)
|
2015-04-17 |
2021-05-31 |
Alpine Immune Sciences Inc |
Immunomodulatory Proteins with Tunable Affinities
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
EP3108897A1
(de)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antikörper gegen menschliches csf-1r für die induzierung von lymphozytose in lymphomen oder leukämien
|
CA2996652A1
(en)
*
|
2015-09-01 |
2017-03-09 |
Immunwork Inc. |
Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
|
US11352426B2
(en)
|
2015-09-21 |
2022-06-07 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
BR112018016461A2
(pt)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
|
CN108699156A
(zh)
|
2016-03-01 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
具有降低的adcp的奥滨尤妥珠单抗和利妥昔单抗变体
|
MX2018012469A
(es)
|
2016-04-15 |
2019-07-04 |
Immunext Inc |
Anticuerpos vista antihumanos y uso de los mismos.
|
KR102514317B1
(ko)
|
2016-04-15 |
2023-03-27 |
마크로제닉스, 인크. |
신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
|
EP3464347B1
(de)
|
2016-06-07 |
2023-05-31 |
Gliknik Inc. |
Cystein-optimierte stradomere
|
EP3257866A1
(de)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modifizierter anti-tnf-antikörper und verwendung davon bei der behandlung von entzündlicher darmerkrankung
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
US11155574B2
(en)
|
2016-12-09 |
2021-10-26 |
Gliknik Inc. |
Manufacturing optimization of GL-2045, a multimerizing stradomer
|
WO2019066603A1
(ko)
|
2017-09-29 |
2019-04-04 |
한미약품 주식회사 |
효력이 향상된 지속성 단백질 결합체
|
CA3077509A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
CN110305221B
(zh)
*
|
2018-03-27 |
2022-10-11 |
孙嘉琳 |
一种增强型抗肿瘤融合蛋白及制备方法及用途
|
CN110305220B
(zh)
*
|
2018-03-27 |
2022-10-11 |
孙嘉琳 |
一种癌靶向增强型抗肿瘤融合蛋白及制备方法及用途
|
CA3110513A1
(en)
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
AU2021306613A1
(en)
|
2020-07-07 |
2023-02-02 |
BioNTech SE |
Therapeutic RNA for HPV-positive cancer
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
WO2023285552A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|